ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Montel Williams Partners With Brothers Grimm Seeds to Release "Montel’s Dream Widow"

Medical Cannabis Advocacy Meets Legendary Genetics in White Widow × Blue Dream Hybrid

JOHNSTOWN, CO / ACCESS Newswire / September 15, 2025 / Brothers Grimm Seeds proudly announces Montel's Dream Widow, a signature cannabis strain created in partnership with Emmy Award-winning television host, decorated veteran, and pioneering medical cannabis advocate Montel Williams. Launching November 30, 2025, this drop merges Montel's decades of advocacy for patients and veterans with Brothers Grimm's mastery of elite cannabis genetics.Montel Williams

Montel Williams

The cross, White Widow × Blue Dream-was personally chosen by Montel for its history, balanced profile, and potential to serve both wellness-minded patients and seasoned connoisseurs. While this pairing has been seen in the past, each cultivar offers a diverse range of phenotypes. Under the direction of founder and Breeding Director Rick "MrSoul" Campanella, Brothers Grimm meticulously hunted and selected the most exceptional phenos to deliver a strain true to Montel's vision of wellness and quality.

The name Montel's Dream Widow was a true community creation-conceived by Montel and confirmed as the top choice in a public strain naming poll hosted by Brothers Grimm, where thousands of fans voted.

As part of the Montel's Dream Widow release, Brothers Grimm Seeds and Montel Williams will donate $1 from every pack sold in the first 30 days to HeroGrown Foundation, a nonprofit dedicated to expanding medical cannabis access for veterans and first responders.

Strain Details

• Montel Williams × Brothers Grimm Seeds

• Strain Name: Montel's Dream Widow

• Genetic Lineage: White Widow × Blue Dream

• Release Date: November 30, 2025

Montel Williams on the Collaboration

"For me, wellness isn't just a goal, it's been my life's mission since my MS diagnosis in 1999," said Montel Williams. "That's why I've partnered with The Brothers Grimm Seeds, a team as passionate about quality as I am, to create Montel's Dream Widow. This isn't just another strain-it's the result of years of my personal wellness journey combined with their trusted expertise in crafting premium genetics. Together, we've thoughtfully created something designed for balance, comfort and quality of life. Wellness starts with intention and my intention with Dream Widow is to give people a premium option they can feel good about."

From Laura "MrsSoul" Campanella, CEO of Brothers Grimm Seeds

"Montel has been a tireless advocate for patients, veterans, and medical access," said Laura "MrsSoul" Campanella. "With Montel's Dream Widow, we're pairing his vision and legacy with our best breeding work to create something meaningful for both home growers and the broader cannabis community."

Beyond the Strain: A Purpose-Driven Campaign

The launch of Montel's Dream Widow goes deeper than genetics. Joint interviews, virtual drop parties, and short-form video content will explore cannabis through the lens of wellness, patient rights, justice, and mental health on Montel's cannabis advocacy podcast, Let's Be Blunt with Montel and BrothersGrimmSeeds.com

Disclaimer:

This product has not been evaluated by the FDA. Brothers Grimm Seeds and Montel Williams make no medical claims. Cannabis effects vary by individual; consumers should consult with a qualified healthcare professional before use.

Contact Information

Marc Emmelmann
Vice President | Brothers Grimm Seeds
marc@brothersgrimmseeds.com

.

SOURCE: Brothers Grimm Seeds



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.